Table 2 Correlation between clinicopathologic parameters, DMFS and DFS.

From: Dysfunctional TLR1 reduces the therapeutic efficacy of chemotherapy by attenuating HMGB1-mediated antitumor immunity in locally advanced colorectal cancer

Parameters

Noa

Stage II

Noa

Stage III

DMFS (%)

p value*

DFS (%)

p value*

DMFS (%)

p value*

DFS (%)

p value*

 

459

68

 

66

 

410

54

 

53

 

Sex

  

0.133

 

0.107

  

0.945

 

0.986

 Female

212

72

 

71

 

189

54

 

53

 

 Male

247

64

 

63

 

221

55

 

53

 

Age

  

< 0.001

 

< 0.001

  

< 0.001

 

< 0.001

 < 65

194

80

 

79

 

194

66

 

65

 

 ≥ 65

265

59

 

57

 

216

44

 

43

 

pT stage

  

NA

 

NA

  

< 0.001

 

< 0.001

 pT1-2

1

0

 

0

 

32

88

 

88

 

 pT3-4

458

68

 

67

 

377

52

 

50

 

Tumor location

  

0.454

 

0.583

  

0.052

 

0.085

 Distal colon

245

69

 

68

 

221

58

 

57

 

 Proximal colon

212

66

 

65

 

186

50

 

50

 

Tumor differentiation

  

0.214

 

0.232

  

0.67

 

0.688

 Well to moderate

448

68

 

67

 

402

54

 

53

 

 Poor

5

40

 

40

 

2

50

 

50

 

Lymphovascular invasion

  

0.010

 

0.005

  

0.039

 

0.021

 Absent

309

71

 

70

 

114

62

 

62

 

 Present

147

61

 

59

 

294

51

 

50

 

Perineural invasion

  

0.055

 

0.033

  

0.008

 

0.002

 Absent

326

71

 

70

 

210

61

 

61

 

 Present

128

62

 

59

 

198

48

 

46

 

TLR1-N248

  

0.34

 

0.36

  

0.019

 

0.026

 WT

82

62

 

61

 

62

68

 

66

 

 Variant

377

69

 

68

 

348

52

 

51

 

TLR2 promoter (− 196 to − 174)

  

0.747

 

0.806

  

0.732

 

0.503

 WT

265

66

 

66

 

229

53

 

51

 

 Variant

193

69

 

67

 

180

56

 

56

 
  1. aNumber of cases may differ due to missing data.
  2. * indicated p < 0.05.